Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer

Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family. Whereas in melanoma patients, the detectio...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 9; no. 12; p. 4376
Main Authors Christine Rentzsch, Simone Kayser, Susanne Stumm, Iris Watermann, Steffen Walter, Stefan Stevanoviç, Diethelm Wallwiener, Brigitte Gückel
Format Journal Article
LanguageEnglish
Published American Association for Cancer Research 01.10.2003
Online AccessGet full text

Cover

Loading…
Abstract Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family. Whereas in melanoma patients, the detection of pre-existing T cell responses to tumor-associated differentiation antigens was a rationale to initiate several vaccination strategies, little is known thus far concerning tumor-specific immunity in breast cancer patients. The objectives of our study were ( a ) to modify and compare different immunodiagnostic T cell assays with regard to their suitability for clinical applications and ( b ) to determine endogenous TAA-specific T cell immunity of breast cancer patients at the time point of primary diagnosis. Experimental Design: Using MUC-1- and Her-2/neu-derived HLA-A*0201-restricted peptides as model antigens, we analyzed antigen-dependent IFN-γ release of T cells by enzyme-linked immunospot (ELISpot) assay, intracellular cytokine flow cytometry (CytoSpot), and quantitative real-time PCR. As an assay independent of T cell function, we performed tetramer staining. Results: In our hands, the quantitative real-time PCR method is most sensitive and a feasible screening test to perform an “immunological staging” of cancer patients. By doing this, we detected in 7 of 13 (54%) of HLA-A*0201 + breast cancer patients a pre-existent specific cellular immune response to at least one of the investigated TAAs (MUC-1, Her-2/neu, carcinoembryonic antigen, NY-ESO-1, and SSX-2). Four of 21 patients (19%) were found to have a significant Her-2/neu-specific T cell response as defined by a stimulation index ≥ 2 (range, 10–88). Conclusions: Although the clinical relevance of endogenous TAA-specific immunity remains unclear, our findings suggest that patients with primary breast cancer can mount a T cell immune response to their tumor that might be beneficially enhanced by TAA-dependent vaccination strategies in the adjuvant situation.
AbstractList Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen, MUC-1, Her-2/neu, and cancer/testis antigens such as NY-ESO-1, SSX-2, and members of the MAGE family. Whereas in melanoma patients, the detection of pre-existing T cell responses to tumor-associated differentiation antigens was a rationale to initiate several vaccination strategies, little is known thus far concerning tumor-specific immunity in breast cancer patients. The objectives of our study were ( a ) to modify and compare different immunodiagnostic T cell assays with regard to their suitability for clinical applications and ( b ) to determine endogenous TAA-specific T cell immunity of breast cancer patients at the time point of primary diagnosis. Experimental Design: Using MUC-1- and Her-2/neu-derived HLA-A*0201-restricted peptides as model antigens, we analyzed antigen-dependent IFN-γ release of T cells by enzyme-linked immunospot (ELISpot) assay, intracellular cytokine flow cytometry (CytoSpot), and quantitative real-time PCR. As an assay independent of T cell function, we performed tetramer staining. Results: In our hands, the quantitative real-time PCR method is most sensitive and a feasible screening test to perform an “immunological staging” of cancer patients. By doing this, we detected in 7 of 13 (54%) of HLA-A*0201 + breast cancer patients a pre-existent specific cellular immune response to at least one of the investigated TAAs (MUC-1, Her-2/neu, carcinoembryonic antigen, NY-ESO-1, and SSX-2). Four of 21 patients (19%) were found to have a significant Her-2/neu-specific T cell response as defined by a stimulation index ≥ 2 (range, 10–88). Conclusions: Although the clinical relevance of endogenous TAA-specific immunity remains unclear, our findings suggest that patients with primary breast cancer can mount a T cell immune response to their tumor that might be beneficially enhanced by TAA-dependent vaccination strategies in the adjuvant situation.
Author Christine Rentzsch
Susanne Stumm
Diethelm Wallwiener
Steffen Walter
Iris Watermann
Stefan Stevanoviç
Brigitte Gückel
Simone Kayser
Author_xml – sequence: 1
  fullname: Christine Rentzsch
– sequence: 2
  fullname: Simone Kayser
– sequence: 3
  fullname: Susanne Stumm
– sequence: 4
  fullname: Iris Watermann
– sequence: 5
  fullname: Steffen Walter
– sequence: 6
  fullname: Stefan Stevanoviç
– sequence: 7
  fullname: Diethelm Wallwiener
– sequence: 8
  fullname: Brigitte Gückel
BookMark eNqVykELgjAcBfARRmr1HXbsImw6Na-JUZ08dB9D_uZCJ2wz89s3oi_Qu7zH4xciT40KViigaZpHSZylntskP0aEJbGPQmOehFBGCdsgn7LUhRQBulUv0U_CylHhscW1hgje0lhQFl-HYVLSLlgqXDviPoNnaTvH5CD0gk8ahLG4FKoBvUPrVvQG9r_eosO5upeXqJOPbpYaePN1GgwI3XS84DTmLMmz5A_6AYDwRfQ
ContentType Journal Article
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
ExternalDocumentID 9_12_4376
GroupedDBID -
08R
29B
2WC
34G
39C
3O-
53G
55
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AETEA
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GJ
GX1
H13
H~9
IH2
KQ8
L7B
LSO
MVM
O0-
OHT
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
VH1
W2D
WOQ
X7M
XFK
XJT
ZA5
ZCG
ZGI
ID FETCH-highwire_cancerresearch_9_12_43763
ISSN 1078-0432
IngestDate Fri Jan 15 19:23:42 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-highwire_cancerresearch_9_12_43763
PMID 14555509
ParticipantIDs highwire_cancerresearch_9_12_4376
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 20031001
PublicationDateYYYYMMDD 2003-10-01
PublicationDate_xml – month: 10
  year: 2003
  text: 20031001
  day: 01
PublicationDecade 2000
PublicationTitle Clinical cancer research
PublicationYear 2003
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
SSID ssj0014104
Score 3.519241
Snippet Purpose: Breast cancers are known to frequently (over)express several well-characterized tumor-associated antigens (TAAs) such as carcinoembryonic antigen,...
SourceID highwire
SourceType Publisher
StartPage 4376
Title Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer
URI http://clincancerres.aacrjournals.org/content/9/12/4376.abstract
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwGA3bHsQX8Yp3IvggjEovaWcfdUznRBk6cW-lSRvwYVW27sH9er9cmkYRnL6Ukpavac_hS5qe7xShUxhiaBZGqZOFAXcIyWKHRiFzaCfKM9ZhuculQPYh6j-TwTgcNxq2amle0nO2-LGu5D-oQhvgKqpk_4CsCQoNsA_4whYQhu1SGPeMVbeUsk1zRxhbluLz_q2s-yhlVd9QeafqQrah9pe4EnL0st0VsE_tOWq3KpZk8lBb-wGZdWPlRyBmp48QdTGrjzwB8NB8l37MatGv1P0UUrE4mRgmQoj2SyrHhaL4svRQi9hKS-0PachikhRHqp4b7aCVXl3h50v0imauU24Iac5Xf4yocnJsU8-3EiwJ1O9iLHTfJxJe4bgOr1txPbBVH_O_jXdGhRgnnp-IgE3UDDyhB70ZG32Q0L8SJVhVXRb2svoSlpm0NRkZraM1_RaBLxUlNlAjLzbRyr3WSWyhQc0M_MaxzQxcMQO_FrhiBhbMwJoZWDEDq-e7jc6ue6Nu36n6kihaVKxIzP0FO6hVAP67CPPU45nLcpoSSsIgpS5nWcoI933uXWTuHjr5Ndz-EuccoNWaMYeoVU7n-RFM30p6LB_zJ9waVkg
link.rule.ids 315,783,787
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+Pre-existent+Immunity+in+Patients+with+Primary+Breast+Cancer&rft.jtitle=Clinical+cancer+research&rft.au=Christine+Rentzsch&rft.au=Simone+Kayser&rft.au=Susanne+Stumm&rft.au=Iris+Watermann&rft.date=2003-10-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=9&rft.issue=12&rft.spage=4376&rft_id=info%3Apmid%2F14555509&rft.externalDBID=n%2Fa&rft.externalDocID=9_12_4376
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon